Erlotinib – 250 mg

Brand:
Cayman
CAS:
183321-74-6
Storage:
-20
UN-No:
Non-Hazardous - /

Erlotinib is a tyrosine kinase inhibitor which acts on the epidermal growth factor receptor (EGFR), inhibiting EGFR-associated kinase activity (IC50 = 2.5 µM).{18354,18362} This inhibits tumor growth in human head and neck carcinoma HN5 tumor xenografts in mice with an ED50 value of 9 mg/kg.{18354} Erlotinib also suppresses cyclin-dependent kinase 2 (Cdk2) activity in breast cancer cells (IC50 = 4.6 µM) and JAK2 mutant JAK2V617F positive hematopoietic progenitor cells (IC50 = 5 µM), which is associated with polycythemia vera, idiopathic myelofibrosis, and essential thrombocythemia.{16061,18355} Formulations containing erlotinib have been used to treat certain forms of cancer, including non-small cell lung cancer.{18351,17857}  

 

Available on backorder

SKU: 10483 - 250 mg Category:

Description

A tyrosine kinase inhibitor which inhibits EGFR-associated kinase activity (IC50 = 2.5 µM) and tumor growth in human HN5 tumor xenografts in mice with an ED50 value of 9 mg/kg; suppresses cyclin-dependent kinase 2 (Cdk2) activity in breast cancer cells (IC50 = 4.6 µM) and JAK2 mutant JAK2V617F positive hematopoietic progenitor cells (IC50 = 5 µM),


Formal name: N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine

Synonyms:  NSC 718781

Molecular weight: 393.4

CAS: 183321-74-6

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Kinase Inhibitors|EGFR/ErbB/HER Family||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Research Area|Cancer|Cell Cycle||Research Area|Cancer|Cell Signaling|Growth Factor Receptor Signaling||Research Area|Cancer|Cell Signaling|JAK/STAT Signaling